Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2015 Financial Results
11 May 2015
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative epilepsy and other neuropsychiatric therapeutics, today provided a business update and announced its financial results for the first quarter ended March 31, 2015.
Clearside Biomedical, Inc. and Santen, Inc. Announce Research Collaboration in Glaucoma
04 May 2015
Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, and Santen Inc., a wholly owned subsidiary of Santen Pharmaceuticals Co., Ltd., today announced the expansion of their research collaboration to include the field of glaucoma.
02 May 2015
Atlas Genetics Ltd., developer of innovative, ultra-rapid diagnostics to enable a ‘test and treat’ solution to infectious diseases, today announces its Annual Summary for 2014.
28 April 2015
Spark Therapeutics, Inc. (NASDAQ: ONCE) and Clearside Biomedical, Inc. announced today that they have entered into an option agreement under which Spark acquired exclusive rights to license Clearside's microinjector technology to deliver gene therapies to the back of the eye. Under the agreement, the companies will explore the feasibility of using Clearside's microinjector technology to deliver viral vectors to the choroid and the retina through the suprachoroidal space (SCS).
Marinus Pharmaceuticals insider Gail M. Farfel Sells 30,000 Shares (MRNS)
24 April 2015
Marinus Pharmaceuticals (NASDAQ:MRNS) insider Gail M. Farfel sold 30,000 shares of Marinus Pharmaceuticals stock on the open market in a transaction that occurred on Tuesday, April 21st. The stock was sold at an average price of $9.48, for a total value of $284,400.00.
Hydrogel Corneal Inlay Promising in Pseudophakic Presbyopia
24 April 2015
A transparent hydrogel corneal inlay is a novel way to correct the vision of patients with pseudophakic presbyopia, a new study shows.
22 April 2015
Ñlearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced the purchase and acquisition of iScience Interventional Corporation’s patent portfolio covering drug delivery to the suprachoroidal space (SCS).
Range of ‘uninterrupted vision’ possible with inlay
20 April 2015
Study patients with a near vision inlay implanted under a femtosecond flap achieved extended depth of focus that ranged from +1 to +3 D, said John A. Hovanesian, MD. The implant (Raindrop Near Vision Inlay, ReVision Optics) is designed to change the curvature of the overlying cornea creating a gradient of power that allows a full range of uninterrupted vision.
Epic Sciences Demonstrates Single Cell Genetic Analysis for Circulating Tumor Cells
16 April 2015
Epic Sciences announced today that its no cell left behind™ technology has successfully integrated single cell isolation and downstream genetic analysis of circulating tumor cells (CTCs) to the platform's capabilities.
Atlas Genetics Enters Into Diagnostic Collaboration With a Major Pharmaceutical Company
15 April 2015
Atlas Genetics Ltd (“Atlas Genetics” or the “Company”), the ultra-rapid ‘test and treat’ molecular diagnostics company, today announces that it has entered into a collaboration with a major pharmaceutical company to develop a diagnostic test, expanding capabilities beyond infectious diseases.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russia has expanded the mandatory health insurance program for 2024-2026
29 March 2024
Russian scientists have developed new TB vaccines for both injection and nasal administration.
29 March 2024
The overall mortality rate of the population in Russia decreased by 7% in 2023
28 March 2024
Russia to collaborate with Hungary and Serbia in nuclear medicine
28 March 2024